Although the existing clinical guidelines recommend ticagrelor and prasugrel is the first choice for patients undergoing percutaneous coronary intervention. But considering that the use of ticagrelor and prasugrel will increase the risk of bleeding in patients with acute coronary syndrome (ACS), clopidogrel is still a very commonly used prescription drug for doctors and remains the second most prescribed drug worldwide.